688317.SH
之江生物
SSE · Healthcare · Biotechnology · CN
CNY 17.17
−2.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 118.1M | 124.8M | 178.7M | 274.3M | 2.3B |
| Cost of Revenue | 41.2M | 44.7M | 69.8M | 95.7M | 1.1B |
| Gross Profit | 76.9M | 80.1M | 108.9M | 178.7M | 1.2B |
| Operating Expenses | |||||
| R&D Expense | 48.9M | 50.9M | 58.8M | 61.0M | 104.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 75.8M | 79.7M | 95.6M | 89.5M | 83.3M |
| Selling & Marketing Expense | 47.4M | 50.3M | 55.6M | 95.2M | 258.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 156.7M | 146.6M | 90.3M | 167.1M | 347.8M |
| Cost and Expenses | 197.9M | 191.3M | 160.1M | 262.8M | 1.5B |
| Operating Income (EBIT) | (56.2M) | (47.6M) | (145.7M) | (149.5M) | 907.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (50.6M) | (42.1M) | (150.6M) | (156.6M) | 901.5M |
| Income Tax Expense | (6.8M) | (7.8M) | (23.1M) | (19.8M) | 141.2M |
| Bottom Line | |||||
| Net Income | (43.8M) | (34.3M) | (127.5M) | (136.9M) | 760.3M |
| Earnings from Cont. Ops | (43.8M) | (34.3M) | (127.5M) | (136.9M) | 760.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (43.8M) | (34.3M) | (127.5M) | (136.9M) | 760.3M |
| Per Share | |||||
| Basic EPS | (CN¥0.25) | (CN¥0.19) | (CN¥0.67) | (CN¥0.71) | CN¥3.93 |
| Diluted EPS | (CN¥0.25) | (CN¥0.19) | (CN¥0.67) | (CN¥0.71) | CN¥3.93 |
| Revenue Per Share | CN¥0.69 | CN¥0.69 | CN¥0.94 | CN¥1.42 | CN¥12.02 |
| Shares | |||||
| Basic Shares Outstanding | 170.1M | 180.5M | 190.2M | 192.8M | 193.5M |
| Diluted Shares Outstanding | 170.1M | 180.5M | 190.2M | 192.8M | 193.5M |
| Profitability Metrics | |||||
| EBITDA | — | 17.7M | (78.6M) | (85.5M) | 964.5M |
| D&A | — | 65.3M | 67.1M | 64.0M | 57.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026